- Home
- PUMP vs TYRA Comparison
PUMP vs TYRA Comparison
Compare PUMP & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUMP
- TYRA
- Stock Information
- Founded
- PUMP 2007
- TYRA 2018
- Country
- PUMP United States
- TYRA United States
- Employees
- PUMP N/A
- TYRA N/A
- Industry
- PUMP Oilfield Services/Equipment
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- PUMP Energy
- TYRA Health Care
- Exchange
- PUMP Nasdaq
- TYRA Nasdaq
- Market Cap
- PUMP 550.9M
- TYRA 576.6M
- IPO Year
- PUMP 2017
- TYRA 2021
- Fundamental
- Price
- PUMP $6.56
- TYRA $10.47
- Analyst Decision
- PUMP Buy
- TYRA Strong Buy
- Analyst Count
- PUMP 5
- TYRA 7
- Target Price
- PUMP $9.75
- TYRA $30.86
- AVG Volume (30 Days)
- PUMP 1.9M
- TYRA 364.1K
- Earning Date
- PUMP 07-30-2025
- TYRA 08-06-2025
- Dividend Yield
- PUMP N/A
- TYRA N/A
- EPS Growth
- PUMP N/A
- TYRA N/A
- EPS
- PUMP N/A
- TYRA N/A
- Revenue
- PUMP $1,397,859,000.00
- TYRA N/A
- Revenue This Year
- PUMP N/A
- TYRA N/A
- Revenue Next Year
- PUMP $9.57
- TYRA N/A
- P/E Ratio
- PUMP N/A
- TYRA N/A
- Revenue Growth
- PUMP N/A
- TYRA N/A
- 52 Week Low
- PUMP $4.61
- TYRA $6.42
- 52 Week High
- PUMP $11.17
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- PUMP 57.76
- TYRA 58.12
- Support Level
- PUMP $6.42
- TYRA $9.93
- Resistance Level
- PUMP $6.71
- TYRA $10.49
- Average True Range (ATR)
- PUMP 0.30
- TYRA 0.59
- MACD
- PUMP 0.02
- TYRA 0.08
- Stochastic Oscillator
- PUMP 76.79
- TYRA 94.30
About PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.